Brewin Dolphin Wealth Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Brewin Dolphin Wealth Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$19K	Hold	253	–	–	﹤0.01%	243
2022 Q1	$23K	Hold	253	–	–	﹤0.01%	241
2021 Q4	$28K	Hold	253	–	–	﹤0.01%	234
2021 Q3	$31.8K	Hold	253	–	–	﹤0.01%	231
2021 Q2	$34.3K	Hold	253	–	–	﹤0.01%	228
2021 Q1	$34.3K	Hold	253	–	–	0.01%	214
2020 Q4	$35.6K	Hold	253	–	–	0.01%	185
2020 Q3	$28.2K	Hold	253	–	–	0.01%	198
2020 Q2	$28.3K	Buy	+253	New	+$24.9K	0.01%	190

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Brewin Dolphin Wealth Management's XBI Position: Q2 2022 in Review

Brewin Dolphin Wealth Management held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q2 2022 at 253 shares worth $19K. The position accounts for ﹤0.01% of the portfolio, ranked #243.

Brewin Dolphin Wealth Management first reported a position in XBI in Q2 2020 and has held it in 9 quarters since. The position peaked at $35.6K in Q4 2020. 706 funds tracked by Wall St. Rank hold XBI as of Q2 2022.

Brewin Dolphin Wealth Management held 253 shares of State Street SPDR S&P Biotech ETF worth $19K as of Q2 2022.
Brewin Dolphin Wealth Management left its State Street SPDR S&P Biotech ETF share count unchanged in Q2 2022.
State Street SPDR S&P Biotech ETF made up ﹤0.01% of Brewin Dolphin Wealth Management's portfolio in Q2 2022, its #243 holding.
Brewin Dolphin Wealth Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2020 and has held it in 9 quarters since.
Brewin Dolphin Wealth Management's State Street SPDR S&P Biotech ETF position peaked at $35.6K in Q4 2020.
706 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2022.

Based on Brewin Dolphin Wealth Management's 13F filing for Q2 2022, filed 14 Nov 2022.